Copper histidine

• Description:

  Copper histidine inhibited Ctr1-mediated cellular uptake of oxaliplatin in vitro without altering oxaliplatin accumulation of platinum or neurotoxicity in DRG tissues in vivo. Copper histidine is administered orally for the treatment of Menkes disease.

• Stability:

  ≥ 2 years

• Purity:

  >98% (HPLC)

• Weight:

  217.69

• Molecular Formula:

  C6H8CuN3O2

• Notes:

  Research use only, not for human use.

• Receptor:

  Others

• CAS Number:

  77280-83-2